These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 7687611)

  • 21. Antibodies directed against a variable and neutralizable region of the HTLV-I envelope surface glycoprotein.
    Londos-Gagliardi D; Armengaud MH; Freund F; Dalibart R; Moze E; Huet S; Legrand E; Guillemain BJ
    Leukemia; 1997 Apr; 11 Suppl 3():38-41. PubMed ID: 9209290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunoreactivity of synthetic peptides, corresponding to B-cellular epitopes of human type I T-lymphotrophic virus structural proteins].
    Rasuli AM; Klepikov NN; Andreev SM; Sidorova MV; Vafina MG; Seniuta NB; Pavlish OA; Syrtsev AV; Gurtsevich VE
    Mol Biol (Mosk); 1993; 27(4):880-7. PubMed ID: 8361494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.
    Desgranges C; Souche S; Vernant JC; Smadja D; Vahlne A; Horal P
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):163-73. PubMed ID: 8198868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of immunodominant epitopes of human T-lymphotropic virus type 1 (HTLV-I) using synthetic peptides.
    Lairmore MD; Lal RB; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):117-22. PubMed ID: 9346842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B*3501 transgenic mice.
    Schönbach C; Nokihara K; Bangham CR; Kariyone A; Karaki S; Shida H; Takatsu K; Egawa K; Wiesmüller KH; Takiguchi M
    Virology; 1996 Dec; 226(1):102-12. PubMed ID: 8941327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
    Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of HTLV-I Env and Tax recombinant peptides in yeast: identification of immunogenic domains.
    Noraz N; Benichou S; Madaule P; Tiollais P; Vernant JC; Desgranges C
    Virology; 1993 Mar; 193(1):80-8. PubMed ID: 7679862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid syncytium formation between human T-cell leukaemia virus type-I (HTLV-I)-infected T-cells and human nervous system cells: a possible implication for tropical spastic paraparesis/HTLV-I associated myelopathy.
    Mor-Vaknin N; Turgeman H; Torgeman A; Wolfson M; Huleihel M; Aboud M
    Cell Biol Int; 1998; 22(2):95-103. PubMed ID: 9878096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation and characterization of monoclonal antibodies against multiple epitopes on the C-terminal half of envelope gp46 of human T-cell leukemia virus type-I (HTLV-I).
    Tanaka Y; Yasumoto M; Nyunoya H; Ogura T; Kikuchi M; Shimotohno K; Shiraki H; Kuroda N; Shida H; Tozawa H
    Int J Cancer; 1990 Oct; 46(4):675-81. PubMed ID: 1698731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Identification of immunoreactive epitopes in proteins coded by gag, env, and pol genes of the type I human T-lymphotropic virus (HTLV-I) using synthetic peptides].
    Iaroslavtseva NG; Ivanov VS; Grebennikova ZhO; Kornilaeva GV; Pashkova TA; Chikin LD; Ostrovskiĭ AG; Andreev SM; Khaitov RM; Karamov EV
    Bioorg Khim; 1995 Oct; 21(10):752-60. PubMed ID: 8573207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46.
    Lairmore MD; Rudolph DL; Roberts BD; Dezzutti CS; Lal RB
    Cancer Lett; 1992 Sep; 66(1):11-20. PubMed ID: 1360328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.
    Horal P; Hall WW; Svennerholm B; Lycke J; Jeansson S; Rymo L; Kaplan MH; Vahlne A
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5754-8. PubMed ID: 1712105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.
    Palker TJ; Riggs ER; Spragion DE; Muir AJ; Scearce RM; Randall RR; McAdams MW; McKnight A; Clapham PR; Weiss RA
    J Virol; 1992 Oct; 66(10):5879-89. PubMed ID: 1326649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of variable regions of the surface envelope glycoprotein of HTLV type I and identification of new major epitopes in the 239-261 region.
    Londos-Gagliardi D; Dalibart R; Geoffre S; Dalbon P; Pouliquen JF; Georges-Courbot MC; Sainte-Foie S; Hajjar C; Georges AJ; Moreau JP; Guillemain B
    AIDS Res Hum Retroviruses; 1996 Jul; 12(10):941-50. PubMed ID: 8798979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heat shock cognate protein 70 is a cell fusion-enhancing factor but not an entry factor for human T-cell lymphotropic virus type I.
    Fang D; Haraguchi Y; Jinno A; Soda Y; Shimizu N; Hoshino H
    Biochem Biophys Res Commun; 1999 Aug; 261(2):357-63. PubMed ID: 10425190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of HTLV-1 gp46 glycoprotein from health carriers and HAM/TSP infected individuals.
    Mota-Miranda AC; Barreto FK; Amarante MF; Batista E; Monteiro-Cunha JP; Farre L; Galvão-Castro B; Alcantara LC
    Virol J; 2013 Mar; 10():75. PubMed ID: 23510700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of the peptide length and amino acid specific substitution in the antigenic activity of the chimeric synthetic peptides, containing the p19 core and gp46 envelope proteins of the HTLV-I virus.
    Marin MH; Rodríguez-Tanty C; Higginson-Clarke D; Bocalandro YM; Peña LP
    Biochem Biophys Res Commun; 2005 Oct; 336(3):983-6. PubMed ID: 16157308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The synthetic peptide P-197 inhibits human T-cell leukemia virus type 1 envelope-mediated syncytium formation by a mechanism that is independent of Hsc70.
    Brighty DW; Jassal SR
    J Virol; 2001 Nov; 75(21):10472-8. PubMed ID: 11581416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SIV envelope glycoprotein epitopes recognized by antibodies from infected or vaccinated rhesus macaques.
    Torres JV; Anderson DE; Malley A; Banapour B; Axthelm MK; Benjamini E; Gardner MB
    J Med Primatol; 1993; 22(2-3):129-37. PubMed ID: 7692056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.
    Arp J; LeVatte M; Rowe J; Perkins S; King E; Leystra-Lantz C; Foung SK; Dekaban GA
    J Virol; 1996 Nov; 70(11):7349-59. PubMed ID: 8892853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.